Zevra Therapeutics (ZVRA) CEO F. Sells $225K of Stock
Zevra Therapeutics' CEO sold 20,000 shares, valued at $224,948, amidst a challenging stock performance.
Reviewed by automated data checks against the source filing. How we make and check alerts
McFarlane Neil F., President and CEO at Zevra Therapeutics, Inc. ($ZVRA), sold 20,000 shares at an average price of $11.25, worth about $224,948, on October 12, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $ZVRA is down 12.2% to date (from the $11.32 close on Oct 12, 2026).
ZVRA
Zevra Therapeutics, Inc.
Key Points
- On October 12, 2026, Neil F. McFarlane sold 20,000 shares of Zevra Therapeutics at $11.25 each, totaling $224,948.
- As of October 16, 2026, Zevra's stock was recently trading around $9.97, significantly below its 50-day moving average of $11.49.
- The company has a market cap of about $590.3 million and is scheduled to report earnings on November 4, 2026.
Get $ZVRA trade alerts by text
We text you when insiders, Congress or big funds trade $ZVRA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Zevra Therapeutics, Inc. alert may contain errors. Disclosures
Neil F. McFarlane, President and CEO of Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), sold 20,000 shares on October 12, 2026, for a total of $224,948 at an average price of $11.25. This sale was part of a planned transaction.
Inside McFarlane's Trade
McFarlane's sale of 20,000 shares reduces his stake in the company. The transaction reflects a strategic move as the stock has been underperforming compared to its recent averages.
Other Institutional Activity in Zevra Therapeutics
Vanguard Capital Management LLC increased its holdings by 169,639 shares, bringing its total to 2,638,910 shares valued at approximately $26.2 million. State Street Corporation added 120,399 shares, totaling 1,681,999 shares worth about $16.7 million. Geode Capital Management, LLC also grew its position by 169,020 shares, ending with 1,540,936 shares valued at around $15.3 million. In contrast, Nantahala Capital Management, LLC reduced its stake by 724,589 shares, now holding 1,797,476 shares worth about $17.9 million.
Zevra Therapeutics, Inc. Stock Down 2.9%
Zevra's shares recently traded around $9.97, which is below its 50-day moving average of $11.49 and its 200-day average of $10.66. The stock is also down about 33.7% from its 52-week high of $15.04. This performance comes as the company prepares for its next earnings report on November 4, 2026.
Recent Earnings
In its trailing twelve months, Zevra reported revenue of $136.1 million with an earnings per share (EPS) of $0.92. The company also boasts a return on equity (ROE) of 34.8% and a net margin of 42.8%, indicating strong profitability.
Analysts Set New Price Targets
On July 27, 2026, Canaccord Genuity maintained a Buy rating with a price target of $20.00, while Guggenheim also kept a Buy rating but lowered its target to $24.00. Citizens upgraded its rating to Market Outperform with a target of $28.00 on August 6, 2026. HC Wainwright reiterated a Buy rating with a target of $26.00 on August 20, 2026. The consensus among analysts suggests a strong buy recommendation with a mean target price of $25.00.
About Zevra Therapeutics
Zevra Therapeutics, Inc. is a biotechnology company focused on developing treatments for rare diseases. Its lead product candidate is KP1077, which is undergoing Phase 3 clinical trials for idiopathic hypersomnia and narcolepsy. The company operates out of Boston, MA, and employs around 61 people.
Bottom Line
Investors should watch for Zevra's upcoming earnings report on November 4, 2026. McFarlane's sale adds to the scrutiny around the stock's recent performance, which is currently below key moving averages. Further insider trades and institutional movements may provide additional insights into market sentiment.
Related Filing Alerts
Source: McFarlane Neil F.'s Form 4 filing on $ZVRA (Oct 12, 2026). Find the original filing: ZVRA Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts